Last $161.16 USD
Change Today +0.43 / 0.27%
Volume 151.7K
TARO On Other Exchanges
Symbol
Exchange
New York
As of 8:04 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

taro pharmaceutical indus (TARO) Snapshot

Open
$160.52
Previous Close
$160.73
Day High
$165.30
Day Low
$160.00
52 Week High
08/29/14 - $165.30
52 Week Low
08/30/13 - $65.25
Market Cap
6.9B
Average Volume 10 Days
103.4K
EPS TTM
$7.86
Shares Outstanding
42.8M
EX-Date
--
P/E TM
20.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for TARO PHARMACEUTICAL INDUS (TARO)

taro pharmaceutical indus (TARO) Related Businessweek News

No Related Businessweek News Found

taro pharmaceutical indus (TARO) Details

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets pharmaceutical products in the United States, Canada, Israel, and internationally. The company offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. It also develops and manufactures active pharmaceutical ingredients for use in its finished dosage form products. The company sells and distributes its products to drug wholesalers and store chains, mass merchandisers, food and retail chains, managed care organizations, generic drug distributors, and others. Taro Pharmaceutical Industries Ltd. was founded in 1959 and is based in Haifa Bay, Israel.

1,342 Employees
Last Reported Date: 07/3/14
Founded in 1959

taro pharmaceutical indus (TARO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

taro pharmaceutical indus (TARO) Key Developments

Taro Pharmaceutical Industries Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2014

Taro Pharmaceutical Industries Ltd. reported unaudited consolidated earnings results for the first quarter ended June 30, 2014. For the quarter, the company reported net sales of $130,230,000 compared to $153,195,000 a year ago. Operating income was $54,493,000 compared to $73,550,000 a year ago. Income before income taxes was $51,225,000 compared to $76,104,000 a year ago. Income from continuing operations was $46,322,000 or $1.08 basic and diluted per share compared to $59,069,000 or $1.32 basic and diluted per share a year ago. Net income attributable to the company was $46,098,000 or $1.08 basic and diluted per ordinary share compared to $58,796,000, $1.32 per basic and diluted per ordinary share for the same period a year ago. Net cash provided by operating activities was $35,734,000 compared to $64,411,000 a year ago. Purchase of property plant & equipment, net of related grants was $6,058,000 compared to $3,898,000 a year ago. The net sales decline is due to the impact of net charges taken to meet contractual obligations associated with price adjustments. Excluding the incremental charges taken over the same period last year, operating income, on a comparable basis, would have increased approximately 30%. A $13 million decrease in net income attributable to the company was due to the impact of the above referenced net charges taken.

Taro Pharmaceutical Industries Ltd. to Report Q2, 2014 Results on Aug 07, 2014

Taro Pharmaceutical Industries Ltd. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Aug 07, 2014

Taro Pharmaceutical Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended March 31, 2014

Taro Pharmaceutical announced unaudited consolidated earnings results for the fourth quarter and year ended March 31, 2014. For the quarter, the company reported net income attributable of $89.6 million or $2.10 basic and diluted income per share on net sales of $187.2 million compared to net income attributable of $49.2 million or $1.10 basic and diluted income per share on net sales of $165.1 million for the corresponding period last year. Net sales increased $22.0 million or 13.3%. Operating income was $101.5 million against $63.1 million of prior year period. Operating income increased 54.3% of net sales, compared to 38.2% of net sales of prior year period. Income from continuing operations was $90 million or $2.10 basic and diluted per share from continuing operations against income from continuing operations of $50.2 million or $1.13 basic and diluted per share from continuing operations of prior year period. Income before income taxes was $107.1 million against $66.3 million of prior year period. For the year, the company reported net income attributable of $360.4 million or $8.14 basic and diluted income per share on net sales of $759.3 million compared to net income attributable of $266.2 million or $5.95 diluted income per share on net sales of $671 million for the last year. Net sales increased $88.3 million or 13.2%. Operating income was $430.3 million against $329 million of prior year period. Income from continuing operations was $362 million or $8.15 basic and diluted per share from continuing operations against income from continuing operations of $268.1 million or $5.98 diluted per share from continuing operations of prior year period. Income before income taxes was $443.9 million against $336 million of prior year. Net cash provided by operating activities was $357.6 million against $249 million of prior year. Purchases of property, plant and equipment amounted to $21.2 million against $9.5 million of prior year. Investment in other intangible assets was $4.6 million against $0.777 million of prior year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TARO:US $161.16 USD +0.43

TARO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TARO.
View Industry Companies
 

Industry Analysis

TARO

Industry Average

Valuation TARO Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TARO PHARMACEUTICAL INDUS, please visit www.taro.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.